21 results match your criteria: "CardioVascular Center CVC[Affiliation]"
Transcatheter Pulmonary Artery Banding for HFrEF: Initial Results: Exercise Hemodynamics From the Ongoing First-in-Human Trial.
JACC Basic Transl Sci
April 2024
Helmsley Electrophysiology Center, Mount Sinai Fuster Heart Hospital, New York, New York, USA.
Embolization of percutaneous left atrial appendage closure devices: Timing, management and clinical outcomes.
Cardiovasc Revasc Med
July 2024
CardioVascular Center (CVC) Frankfurt, Frankfurt, Germany.
Article Synopsis
- Left atrial appendage (LAA) occluder embolization is a rare but critical complication occurring mostly within the first 24 hours after the procedure, with data collected from 67 centers on 108 patients.
- The management strategies included attempting percutaneous retrieval in 75% of cases, while 21.3% of patients underwent surgery without prior attempts, highlighting significant mortality rates associated with multiple retrieval attempts.
- Overall, a major adverse event rate of 43.5% was observed, underscoring the serious risks, including death, particularly following unsuccessful retrievals.
LAA occlusion is effective and safe in very high-risk atrial fibrillation patients with prior stroke: results from the multicentre German LAARGE registry.
Clin Res Cardiol
October 2024
Department of Cardiology, Angiology, Haemostaseology and Medical Intensive Care, University Medical Centre Mannheim (UMM), Medical Faculty Mannheim, Heidelberg University, European Center for AngioScience (ECAS), and German Center for Cardiovascular Research (DZHK) Partner Site Heidelberg/Mannheim, Theodor-Kutzer-Ufer 1-3, 68167, Mannheim, Germany.
Article Synopsis
- Interventional left atrial appendage occlusion (LAAO) is effective for patients with nonvalvular atrial fibrillation (AF) who can't use long-term blood thinners, especially those with a history of stroke.
- A study from the LAARGE registry found that LAAO was similarly effective and safe for stroke patients compared to those without a stroke history, with high success rates and low complication rates in both groups.
- The results suggest that LAAO could be a viable option for secondary prevention in high-risk AF patients, showing no significant differences in risk of death or stroke between those with and without prior strokes.
Is spontaneous echo contrast associated with device-related thrombus or embolic events after left atrial appendage occlusion? - Insights from the multicenter German LAARGE registry.
J Interv Card Electrophysiol
January 2024
Department of Cardiology, Städtisches Klinikum Lüneburg gGmbH, Lüneburg, Germany.
Article Synopsis
- Interventional left atrial appendage occlusion (LAAO) is a treatment option that replaces long-term oral anticoagulation for patients with nonvalvular atrial fibrillation, particularly those with a high risk of bleeding.
- A study examined the impact of spontaneous echo contrast (SEC) on the risk of device-related thrombus (DRT) and thromboembolic events (TEs) in two groups of patients: those with SEC and those without it.
- The results showed that while procedural success was high in both SEC groups, DRT was only noted in the SEC- group and TEs were rare in both, suggesting that SEC presence might not significantly affect post-LAAO outcomes.
Real-world experience with the cusp-overlap deployment technique in transcatheter aortic valve replacement: A propensity-matched analysis.
Front Cardiovasc Med
August 2022
Department of Cardiology, Pulmonology and Vascular Medicine, Medical Faculty, Heinrich Heine University, Düsseldorf, Germany.
Background: The implantation depth (ID) is a critical condition for optimal hemodynamic and clinical outcomes in transcatheter aortic valve replacement (TAVR). The recently recommended cusp-overlap technique (COT) offers optimized fluoroscopic projections facilitating a precise ID. This single-center observational study aimed to investigate short-term clinical performance, safety, and efficacy outcomes in patients undergoing TAVR with self-expandable prostheses and application of COT in a real-world setting.
View Article and Find Full Text PDFCerebrovascular Events after Transcatheter Aortic Valve Replacement: The Difficulty in Predicting the Unpredictable.
J Clin Med
July 2022
Department of Cardiology, Pulmonology and Vascular Medicine, Medical Faculty, Heinrich Heine University, 40225 Duesseldorf, Germany.
Background: Cerebrovascular events (CVE) are feared complications following transcatheter aortic valve replacement (TAVR). We aimed to develop a new risk model for CVE prediction with the application of multimodal imaging. Methods: From May 2011 to August 2019, a total of 2015 patients underwent TAVR at our institution.
View Article and Find Full Text PDFAdverse events and stroke prevention by interventional left atrial appendage occlusion in patients with low CHA DS -VASc score-results from the multicenter German LAARGE registry.
Catheter Cardiovasc Interv
June 2022
Department of Cardiology, Angiology, Haemostaseology and Medical Intensive Care, University Medical Centre Mannheim, Medical Faculty Mannheim, Heidelberg University, European Center for AngioScience (ECAS), and German Center for Cardiovascular Research (DZHK) Partner Site Heidelberg/Mannheim, Mannheim, Germany.
Article Synopsis
- Interventional left atrial appendage occlusion (LAAO) is a procedure used for patients with nonvalvular atrial fibrillation who cannot take standard blood thinners, and this study looks at its effects on patients with low versus high stroke risk.
- The study included 638 patients divided into low-risk (CHA DS -VASc score ≤2) and high-risk (score >2) groups, finding that while implantation success was high, low-risk patients experienced more moderate complications despite having no major strokes or bleeds within a year.
- The authors suggest that the need for LAAO in low-risk patients should be carefully evaluated to weigh potential benefits against risks.
Anticoagulation versus antiplatelet therapy after percutaneous left atrial appendage closure-subanalysis from the multicenter LAARGE registry.
J Interv Card Electrophysiol
August 2022
Klinik Für Kardiologie, Pneumologie Und Intern. Intensivmed., Klinikum Neuperlach, Oskar-Maria-Graf-Ring 51, 81737, München, Germany.
Purpose: Data regarding post-procedural antithrombotic therapy following percutaneous left atrial appendage (LAA) in real-world populations using various occluder systems is limited. In the present analysis, anticoagulation (AC) was compared against antiplatelet therapy (APT) using data from the real-world multi-center LAARGE study.
Methods: Patients following LAA closure enrolled in the LAARGE study were assigned to two groups depending on initial post-implantation antithrombotic regime consisting of either AC or APT.
Background: Residual peri-device leakage (PDL) is frequent after left atrial appendage occlusion (LAAO). Little is known about management strategies, procedural aspects and outcomes of interventional PDL closure.
Aims: The aim of this study was to assess the safety and feasibility of PDL closure after LAAO.
Initial and long-term antithrombotic therapy after left atrial appendage closure with the WATCHMAN.
Europace
July 2020
CardioVascular Center CVC, Seckbacher Landstraße 65, 60389 Frankfurt, Germany.
Aims: Evidence regarding post-procedural antithrombotic regimen other than used in randomized trials assessing percutaneous left atrial appendage (LAA) closure is limited. The present work aimed to compare different antithrombotic strategies applied in the real-world EWOLUTION study.
Methods And Results: A total of 998 patients with successful WATCHMAN implantation were available for the present analysis.
WATCHMAN versus ACP or Amulet devices for left atrial appendage occlusion: a sub-analysis of the multicentre LAARGE registry.
EuroIntervention
December 2020
CardioVascular Center CVC, Frankfurt, Germany.
Aims: Several left atrial appendage (LAA) closure systems are available. Due to differences in device design, the results of specific occluders derived from trials cannot simply be generalised to all devices. The present analysis sought to assess two contemporary LAA closure devices in clinical practice.
View Article and Find Full Text PDFLeft atrial appendage closure in patients with chronic kidney disease: results from the German multicentre LAARGE registry.
Clin Res Cardiol
January 2021
First Department of Medicine, University Medical Centre Mannheim (UMM), Faculty of Medicine Mannheim, University of Heidelberg, European Center for AngioScience (ECAS), and DZHK (German Center for Cardiovascular Research) Partner Site Heidelberg/Mannheim, Theodor-Kutzer-Ufer 1-3, 68167, Mannheim, Germany.
Article Synopsis
- The study explores the impact of chronic kidney disease (CKD) on complications and outcomes following left atrial appendage closure (LAAC) in patients with atrial fibrillation.
- About 48% of the 623 participants had CKD, showing higher cardiovascular risks but similar success rates for the procedure across different kidney function levels.
- Although CKD patients faced a lower survival rate free of stroke within a year, LAAC proved safe and effective for stroke prevention, regardless of the severity of kidney impairment.
Left atrial appendage closure in patients with a reduced left ventricular ejection fraction: results from the multicenter German LAARGE registry.
Clin Res Cardiol
November 2020
First Department of Medicine, University Medical Centre Mannheim (UMM), Faculty of Medicine Mannheim, University of Heidelberg, Theodor-Kutzer-Ufer 1-3, 68167, Mannheim, Germany.
Article Synopsis
- - The study investigates the effectiveness of left atrial appendage closure (LAAC) in patients with atrial fibrillation and varying levels of left ventricular ejection fraction (LVEF), revealing that LVEF reduction does not significantly affect procedural success or safety during the procedure.
- - A total of 619 patients from 37 centers were analyzed, showing that lower LVEF correlates with increased cardiovascular comorbidity but similar rates of procedural complications across all LVEF categories.
- - Despite a trend towards reduced stroke-free survival associated with lower LVEF, the findings suggest that the LAAC procedure remains effective and safe, regardless of LVEF levels, emphasizing its utility in high-risk patient populations.
EHRA/EAPCI expert consensus statement on catheter-based left atrial appendage occlusion - an update.
Europace
February 2020
Cardiology, Cardiovascular Department, University Hospital Bern, Bern, Switzerland.
The presence of a patent foramen ovale (PFO) is implicated in the pathogenesis of a number of medical conditions; however, the subject remains controversial and no official statements have been published. This interdisciplinary paper, prepared with involvement of eight European scientific societies, aims to review the available trial evidence and to define the principles needed to guide decision making in patients with PFO. In order to guarantee a strict process, position statements were developed with the use of a modified grading of recommendations assessment, development, and evaluation (GRADE) methodology.
View Article and Find Full Text PDFSubclinical leaflet thrombosis.
Lancet
March 2018
Division of Cardiology, Pulmonology and Vascular Medicine, University Hospital Düsseldorf, Düsseldorf 40225, Germany. Electronic address:
Proceedings from the 2nd European Clinical Consensus Conference for device-based therapies for hypertension: state of the art and considerations for the future.
Eur Heart J
November 2017
The Lambe Institute for Translational Medicine and Curam, National University of Ireland, Galway, Ireland.
Association Between Chronic Kidney Disease and Rates of Transfusion and Progression to End-Stage Renal Disease in Patients Undergoing Transradial Versus Transfemoral Cardiac Catheterization-An Analysis From the Veterans Affairs Clinical Assessment Reporting and Tracking (CART) Program.
J Am Heart Assoc
April 2017
Durham VA Medical Center, Durham, NC.
Background: Patients with chronic kidney disease (CKD) are at increased risk for bleeding, transfusion, and dialysis after cardiac catheterization. Whether rates of these complications are increased in this high-risk population undergoing transradial access compared with transfemoral access is unknown.
Methods And Results: From the Veterans Affairs (VA) Clinical Assessment Reporting and Tracking program, we identified 229 108 patients undergoing cardiac catheterization between 2007 and 2014, of which 48 155 (21.
Transcatheter mitral valve repair with the MitraClip(®) can be performed without general anesthesia and without conscious sedation.
Clin Res Cardiol
April 2016
CardioVascular Center CVC, Sankt Katharinen Hospital, Seckbacher Landstraße 65, 60389, Frankfurt, Germany.
Background: General anesthesia is known to be associated with an increased risk for complications, especially in elderly and multi-morbid patients, the primary target population of the MitraClip(®) technique. The aim is to assess whether general anesthesia and even conscious sedation can be avoided during the MitraClip(®) procedure.
Methods: A total of 91 consecutive patients who underwent MitraClip(®) implantation [median 77 years, (IQR 72-83), 40 % female] were retrospectively analyzed.
Left atrial appendage closure: First in man with the 4th generation WATCHMAN device.
Catheter Cardiovasc Interv
March 2016
CardioVascular Center CVC, Frankfurt, Germany.
Objectives: To evaluate the feasibility and safety of the fourth generation WATCHMAN device.
Background: The WATCHMAN left atrial appendage (LAA) closure device has been shown to be non-inferior to conventional oral anticoagulation with warfarin for stroke prevention in patients with non-valvular atrial fibrillation. A new (fourth) generation of the WATCHMAN device was designed to facilitate easier delivery and improve safety.
Background: MitraClip® therapy is an alternative to conventional surgery. The aim was to characterize the mitral annular geometry pre- and postrepair with the MitraClip® taking into account the regurgitation mechanism.
Methods: We retrospectively collected pre- and postprocedural transesophageal echocardiography data in 46 patients.